Ovimec 0.8 mg/ml Oral Solution for Sheep

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Abamectin

Available from:

Bimeda Animal Health Limited

ATC code:

QP54AA02

INN (International Name):

Abamectin

Dosage:

0.8 milligram(s)/millilitre

Pharmaceutical form:

Oral solution

Prescription type:

LM: Licensed Merchant as defined in relevant national legislation

Therapeutic area:

abamectin

Authorization status:

Authorised

Authorization date:

2005-06-03

Summary of Product characteristics

Health Products Regulatory Authority
03 May 2019
CRN008M6W
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Ovimec 0.8 mg/ml Oral Solution for Sheep.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
​
Active Substance:
​
​
Abamectin
​0.8 mg
​
​
​
Excipients:
​
​
Benzyl Alcohol
​30.0 mg
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Oral Solution.
A clear, pale yellow solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
A broad spectrum endectocide of the avermectin family. For the
treatment and control of the following gastro-intestinal
nematodes, lungworms and nasal bots roundworms of sheep:
Gastro-intestinal nematodes:

​_Haemonchus contortus_ (adult, L
4
)

_Ostertagia circumcincta_ (adult, L
4
and inhibited larval stages)

_Ostertagia trifurcata_ (adult)

_Trichostrongylus axei_ (adult)

_Trichostrongylus vitrinus_ (adult and L
4
)

_Trichostronylus colubriformis_ (adult and L
4
)

_Cooperia curticei_ (adult and L
4
)

_Nematodirus battas_ (adult and L
4
)

_Nematodirus filicollis_ (adult)

_Strongyloides papillosus_ (adult)

_Oesophagostomum venulosum_ (adult)

_Trichuris ovis_ (adult)

_Chabertia ovina_ (adult)
Lungworms:

​_Dictyocaulus filaria_ (adult and L
4
)
Nasal bot

​_Oestrus ovis_ (all larval stages)
Health Products Regulatory Authority
03 May 2019
CRN008M6W
Page 2 of 5
4.3 CONTRAINDICATIONS
Do not concurrently treat animals with drugs, which can increase GABA
activity such as barbital.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk of development of resistance and could
ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
- Underdosing which may be due to underestimation of bodyweight,
misadministration of the product, or